Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Zealand Pharma A/S    ZEAL   DK0060257814

ZEALAND PHARMA A/S

(ZEAL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
07/07/2020 07/08/2020 07/09/2020 07/10/2020 07/13/2020 Date
241(c) 242.2(c) 238.6(c) 235.4(c) 231.8 Last
82 522 77 494 134 456 79 669 81 377 Volume
-0.17% +0.50% -1.49% -1.34% -1.53% Change
More quotes
Financials
Sales 2020 346 M 52,6 M 52,6 M
Net income 2020 -616 M -93,7 M -93,7 M
Net cash position 2020 742 M 113 M 113 M
P/E ratio 2020 -14,3x
Yield 2020 -
Sales 2021 295 M 44,9 M 44,9 M
Net income 2021 -716 M -109 M -109 M
Net cash position 2021 621 M 94,5 M 94,5 M
P/E ratio 2021 -12,4x
Yield 2021 -
Capitalization 9 338 M 1 418 M 1 421 M
EV / Sales 2020 24,9x
EV / Sales 2021 29,5x
Nbr of Employees 191
Free-Float 99,7%
More Financials
Company
Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and... 
More about the company
Surperformance© ratings of Zealand Pharma A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on ZEALAND PHARMA A/S
07/06Zealand Pharma Expands U.S. Operations, Opens New Boston Office
GL
06/24ZEALAND PHARMA A/S : announces first patient dosed in Phase 2 trial with long-ac..
AQ
06/23ZEALAND PHARMA MAJOR SHAREHOLDER ANN : Sunstone Life Science Ventures
AQ
06/22ZEALAND PHARMA A/S : completes registration of capital increase
AQ
06/17ZEALAND PHARMA A/S : announces completion of directed issue and private placemen..
AQ
06/17ZEALAND PHARMA A/S : announces directed issues and private placements of up to a..
AQ
06/15ZEALAND PHARMA A/S : increases its share capital as a consequence of exercise of..
AQ
06/15Zealand Pharma strengthens executive team with new U.S. leadership
GL
06/14Zealand Pharma presents clinical and non-clinical evidence for dasiglucagon r..
GL
06/13ZEALAND PHARMA A/S : presents elaborated results on the use of regular human ins..
AQ
06/12ZEALAND PHARMA A/S : increases its share capital as a consequence of exercise of..
AQ
06/10Zealand Pharma to leverage Intomics bioinformatics platform within peptide dr..
GL
06/01Zealand Pharma to attend Jefferies and Goldman Sachs Virtual Healthcare Confe..
GL
05/26ZEALAND PHARMA A/S : increases its share capital as a consequence of exercise of..
AQ
05/22Zealand Pharma announces FDA acceptance of New Drug Application for the dasig..
GL
More news
News in other languages on ZEALAND PHARMA A/S
07/06ZEALAND PHARMA : va ouvrir des bureaux à Boston
07/06Zealand Pharma Expands U.S. Operations, Opens New Boston Office
06/24ZEALAND PHARMA A/S : announces first patient dosed in Phase 2 trial with long-ac..
06/23ZEALAND PHARMA MAJOR SHAREHOLDER ANN : Sunstone Life Science Ventures
06/22ZEALAND PHARMA A/S : completes registration of capital increase
More news
Chart ZEALAND PHARMA A/S
Duration : Period :
Zealand Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZEALAND PHARMA A/S
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 292,57 DKK
Last Close Price 235,40 DKK
Spread / Highest target 67,8%
Spread / Average Target 24,3%
Spread / Lowest Target -4,42%
EPS Revisions
Managers
NameTitle
Emmanuel Dulac President & Chief Executive Officer
Alf Gunnar Martin Nicklasson Chairman
Ivan M. Møller Senior VP-Technical Development & Operations
Matthew D. Dallas Chief Financial Officer & Senior Vice President
Adam Sinding Steensberg Chief Medical & Development Officer, Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
ZEALAND PHARMA A/S0.00%1 418
GILEAD SCIENCES, INC.17.45%95 734
VERTEX PHARMACEUTICALS34.48%76 344
REGENERON PHARMACEUTICALS65.35%63 051
WUXI APPTEC CO., LTD.53.97%33 311
GENMAB A/S56.13%22 955